报价延迟最少15分钟:2026/09/24 10:26 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.51 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12.52/2.34
|
|
企业价值
5.52B
|
| 资产负债 |
|
每股账面净值
18.13
|
| 现金流量 |
|
现金流量率
0.10
|
| 损益表 |
|
收益
4.25B
|
|
每股收益
33.54
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne. |
